Agenda features discussion of life sciences industry trends, business value of model-informed drug development strategies, and impact of generative AI on biosimulation and regulatory sciences RADNOR, PA– April. 18, 2024 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will host the first-ever Certainty Conference. At this event, … Continued
New, spacious location in Radnor, Pennsylvania will support the needs of company’s growing workforce and business, strengthen presence in the state RADNOR, PA – April 15, 2024 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the relocation of its corporate headquarters to Radnor, Pennsylvania. The new headquarters is 13 … Continued
PRINCETON, N.J.— December 1, 2023 – Certara, Inc., a global leader in biosimulation, today announced the release of version 23.10.1 of Pirana, a workbench solution that simplifies and harmonizes the use of multiple toolsets commonly used for pharmacometrics analysis, including tools like Certara’s R speaks NLME. This release continues to expand the machine learning capabilities … Continued
PRINCETON, N.J.— November 1 2023, Certara (Nasdaq: CERT), a global leader in biosimulation, today announced that the Company was listed on Fortune’s Best Workplaces in BioPharma™ 2023 and was certified as a Great Place to Work for the second year in a row. The prestigious certification is based on what current Certara employees say about … Continued
Certara University offers 3 Introductory level Certification Courses. These courses are administered within the learning system of Certara University. You can view additional details and register using the links in the table below. Certification Course Registration Link Price* Phoenix WinNonlin (Part 1) NCA Certification Course Live On-Line – January – February 2024 – June – … Continued
Formedix ryze cloud based clinical metadata repository and SDTM automation suite and Certara Pinnacle 21 data validation platform combine to power faster clinical trials Princeton, NJ – October 10th, 2023 – Certara, Inc. (Nasdaq: CERT) today announced it has acquired Formedix, a provider of clinical metadata repository and clinical trial automation software. The acquisition enhances … Continued
Certara.AI Improves Drug Research & Development Processes with Secure, Client-Specific, A.I. Applications PRINCETON, N. J.—October 5, 2023— Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation software, today announced the availability of Certara.AI, a platform designed specifically for the deployment of client-specific generative pre-trained transformers (GPTs) in Life sciences organizations. The majority of GPT models … Continued
Using AI to gain efficiencies for medical writers PRINCETON, N. J.— October 3, 2023— Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation software and advanced drug development solutions, today announced the launch of CoAuthor, a writing software suite designed to revolutionize the creation and review of critical clinical trial documents in the pharmaceutical industry. … Continued
Certara launches Phoenix Hosted, a cloud-based solution of Phoenix™ software PRINCETON, N.J.— September 19, 2023 – Certara, Inc., a global leader in biosimulation software, today announced the release of Phoenix Hosted. The cloud-based solution Phoenix Hosted empowers PK/PD scientists with seamless access to the industry-leading Phoenix™ WinNonlin and NLME software, within a secured and validated … Continued
Delivers advanced data analysis and visualization capabilities to support nonclinical scientists PRINCETON, N.J.— August 28, 2023 – Certara, Inc., a global leader in biosimulation, today announced the release of version 11.0 of the SEND Explorer® Product Family. SEND Explorer allows scientists to interactively investigate study data, to efficiently identify dose-response relationships and to effectively communicate data … Continued
